

ASX ANNOUNCEMENT

1 October 2025

Biome reports record quarterly sales revenue for Q1 FY26

- Biome achieves record quarterly sales revenue of \$5.94m
- Sales revenue exceeded forecast target of \$5.5m by \$440k or 8%
- Sales revenue increased 40% vs PCP (Q1 FY25)
- Sales revenue increased 19% QoQ (Q4 FY25)
- Q1 sales revenue represents a ~\$23.7m annualised run rate (ARR)
- Company remains on track to achieve Vision 27 three-year revenue guidance

Microbiome health company *Biome Australia Limited* (ASX: BIO) ('*Biome*' or '*the company*') is pleased to provide a trading update for Q1 FY26.

Biome's quarterly sales revenue totalled \$5.94m, representing a 19% increase above the previous record quarter (Q4 FY25, \$5.0m) and a 40% increase versus PCP. This result exceeded the company's forecast target of \$5.5m (Ref: ASX announcement dated 3 September 2025) by \$440k or 8%.

Biome's Q1 sales revenue represents an annualised run rate of \$23.7m, with growth expected to continue through the remainder of FY26. *The company's* strong growth trajectory places it on track to achieve its Vision 27 three-year revenue guidance of at least \$75m, demonstrating continued momentum toward *Biome's* strategic targets.

The underlying business performance continues to strengthen, with *Biome's Activated Probiotics* being offered increased shelf space in the competitive practitioner-only category within pharmacy within Q1. The brand has delivered more than 50% sell-through growth in pharmacy over the past 12 months, compared to expected category growth of only ~6%,¹ representing more than eight times outperformance. This exceptional sell-through growth from the existing customer base demonstrates the strength of *Biome's* market position and product demand.

Biome Australia's Managing Director and Founder, Blair Vega Norfolk, commented:

"I am excited to share this exceptional result for Q1 FY26, marking another record quarter in sales revenue and demonstrating the continued momentum in our business. Exceeding our forecast by 8% and achieving 19% growth over our previous record quarter and 40% growth versus PCP reinforces the strength of our Activated Probiotics platform and the robust demand we're seeing across all channels. Our strong performance maintains our positive trajectory toward achieving our Vision 27 targets, and I look forward to sharing further updates on our growth in the coming periods."

-ENDS-

This announcement has been authorised for release by the Board of Biome Australia Limited.

¹ <https://cmaustralia.org.au/wp-content/uploads/CMA-Snapshot-2024.pdf>



About Biome Australia Limited

Biome Australia develops, licenses, commercializes and markets innovative, evidence-based live biotherapeutics (probiotics) and complementary medicines supported by clinical research. Biome aims to improve health outcomes and quality of life, making products accessible through professional health channels.

Incorporated in Australia in 2018, Biome distributes locally and internationally. In partnership with leading microbiome research organizations, Biome produces unique live biotherapeutic products with innovative delivery technologies improving stability and efficacy for its flagship Activated Probiotics® range.

Supported by randomized double-blind placebo-controlled clinical trials, Activated Probiotics® and Activated Therapeutics® help prevent and support management of various health concerns including low mood and sleep, bone health, iron malabsorption, mild eczema and IBS. Through practitioner-recommended distribution, Biome educates health professionals on gut microbiota's systemic health effects, providing evidence-based natural medicines for prevalent chronic health concerns.


For more information visit: www.biomeaustralia.com

Investor Relations
Rechelle Friend
corporate@biomeaustralia.com

Media enquiries
media@activated.co

Forward Looking Statements

This release contains forward looking statements, including projections, guidance on future revenues, earnings and estimates regarding Biome's future performance (Forward Looking Statements). Forward Looking Statements are provided as general guidance only and should not be relied upon as indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in Forward Looking Statements. Such statements assume success of Biome's business strategies. You are cautioned not to place undue reliance on Forward Looking Statements.



Forward Looking Statements are based on information available to Biome as at the date of this release. Nothing in this release is a promise or representation as to the future. No representation or warranty, express or implied, is made as to accuracy, likelihood of achievement or reasonableness of Forward Looking Statements contained in this release. Except as required by law or regulation (including ASX Listing Rules), Biome does not undertake to provide additional or updated information whether as result of changed expectations, new information, future events or otherwise.

To the maximum extent permitted by law, Biome excludes and expressly disclaims all liabilities in respect of, and makes no representation or warranty, express or implied as to fairness, currency, accuracy, reliability or completeness of information in this release or accuracy, likelihood of achievement or reasonableness of Forward Looking Statements contained in, implied by, or part of this release, or that this release contains all material information about Biome which prospective investors may require in evaluating possible investment in Biome.

